Page 53 - 2019_10 resto del Mondo_web

Criteria and standards in CMML
rantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma. 2011;52(1):92-100.
124.Shen Q, Ouyang J, Tang G, et al. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol. 2015;95(2):168-176.
125. Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al; Francophone Myelodysplasia Group. Characteristic repartition of mono- cyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125(23):3618-3626.
126. Harrington AM, Schelling LA, Ordobazari A, Olteanu H, Hosking PR, Kroft SH. Immunophenotypes of chronic myelomono- cytic leukemia (CMML) subtypes by flow cytometry: a comparison of CMML-1 vs CMML-2, myeloproliferative vs dysplastic, de novo vs therapy-related, and CMML-spe- cific cytogenetic risk subtypes. Am J Clin Pathol. 2016;146(2):170-181.
127. Selimoglu-Buet D, Badaoui B, Benayoun E, et al; Groupe Francophone des Myélodysplasies. Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood. 2017;130(6):832-835.
128.Picot T, Aanei CM, Flandrin Gresta P, et al. Evaluation by flow cytometry of mature monocyte subpopulations for the diagnosis and follow-up of chronic myelomonocytic leukemia. Front Oncol. 2018;8:109.
129. Hudson CA, Burack WR, Leary PC, Bennett JM. Clinical utility of classical and nonclassi- cal monocyte percentage in the diagnosis of chronic myelomonocytic leukemia. Am J Clin Pathol. 2018;150(4):293-302.
130. Feng R, Bhatt VR, Fu K, Pirruccello S, Yuan J. Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Cytometry B Clin Cytom. 2018;94(6):901- 909.
131. Hudson CA, Burack WR, Bennett JM. Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia. Leuk Res. 2018;73:12-15.
132.Talati C, Zhang L, Shaheen G, et al. Monocyte subset analysis accurately distin-
guishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017;129(13):1881-1883.
133. Damasceno D, Teodosio C, van den Bossche WBL, et al, on behalf of the TiMaScan Study Group. Distribution of subsets of blood monocytic cells throughout life. J Allergy Clin Immunol. 2019;144(1):320-323.e5.
134. Escribano L, Garcia Montero AC, Núñez R, Orfao A; Red Española de Mastocitosis. Flow cytometric analysis of normal and neo- plastic mast cells: role in diagnosis and fol- low-up of mast cell disease. Immunol Allergy Clin North Am. 2006;26(3):535-547.
135.Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
136.Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retro- spective analysis of 213 patients. Blood. 2002;99(3):840-809.
137.Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121 (15):3005-3015.
138. Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for CMML vali- dates prognostic scoring systems and demonstrates a need for novel prognostica- tion strategies. Blood Cancer J. 2015;5:e333.
139. Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014;12(3):172-178.
140.Pleyer L, Germing U, Sperr WR, et al. Azacitidine in CMML: matched-pair analy- ses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014;38(4):475-483.
myelomonocytic leukemia in a new era. Curr
Hematol Malig Rep. 2017;12(5):468-477. 144.Hunter AM, Zhang L, Padron E. Current management and recent advances in the treatment of chronic myelomonocytic leukemia. Curr Treat Options Oncol.
2018;19(12):67.
145. Diamantopoulos PT, Kotsianidis I,
Symeonidis A, et al; Hellenic MDS Study Group. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. Leuk Lymphoma. 2018;14:1-10.
146.Itzykson R, Fenaux P, Bowen D, et al, on behalf of the European Hematology Association, the European LeukemiaNet. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: rec- ommendations from the European Hematology Association and the European LeukemiaNet. HemaSphere. 2018;2(6): e150.
147.Eissa H, Gooley TA, Sorror ML, et al. Allogeneic hematopoietic cell transplanta- tion for chronic myelomonocytic leukemia: relapse-free survival is determined by kary- otype and comorbidities. Biol Blood Marrow Transplant. 2011;17(6):908-915.
148.de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell trans- plantation for MDS and CMML: recommen- dations from an international expert panel. Blood. 2017;129(13):1753-1762.
149.Onida F, Barosi G, Leone G, et al. Management recommendations for chronic myelomonocytic leukemia: consensus state- ments from the SIE, SIES, GITMO groups. Haematologica. 2013;98(9):1344-1352.
150. Savona MR, Malcovati L, Komrokji R, et al; MDS/MPN International Working Group. An international consortium proposal of uniform response criteria for myelodysplastic/ myelo- proliferative neoplasms (MDS/ MPN) in adults. Blood. 2015;125(12): 1857-1865.
151. Drechsler M, Hildebrandt B, Kündgen A, Germing U, Royer-Pokora B. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol. 2007;86(5):353-354.
141.
Padron E, Steensma DP. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies. Curr Opin Hematol. 2015;22(2):163-170.
142.Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood. 2017;130 (2):126-136.
143. Moyo TK, Savona MR. Therapy for chronic
haematologica | 2019; 104(10)
1949